FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy

In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, c...

Descripción completa

Detalles Bibliográficos
Autores principales: Drożdżal, Sylwester, Rosik, Jakub, Lechowicz, Kacper, Machaj, Filip, Kotfis, Katarzyna, Ghavami, Saeid, Łos, Marek J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362818/
https://www.ncbi.nlm.nih.gov/pubmed/32717568
http://dx.doi.org/10.1016/j.drup.2020.100719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362818/
https://www.ncbi.nlm.nih.gov/pubmed/32717568
http://dx.doi.org/10.1016/j.drup.2020.100719

Ejemplares similares